AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27213613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lancet weight of 85 g
Number of subjects: 20
Study 27213613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lancet weight of 135 g
Number of subjects: 20
Study 27213613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lancet weight of 265 g
Number of subjects: 20
Study 27213613 — intervention group
Group type: COMPARATOR
Intervention: Saline (negative control)
Number of subjects: 20
Study 27213613 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine 1 mg/mL (positive control)
Number of subjects: 20
Study 27213613 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine 10 mg/mL (positive control)
Number of subjects: 20
Study 23692706 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 4μg/kg
Number of subjects: 104
Study 23692706 — intervention group
Group type: COMPARATOR
Intervention: Control (saline placebo)
Number of subjects: 104
Study 20932788 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical pain test (pressure) at lower back, suprascapular region, and second toe.
Number of subjects: 300
Study 20932788 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal pain test (heat and cold) at lower back, suprascapular region, and lateral aspect of the leg.
Number of subjects: 300
Study 20932788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (withdrawal time).
Number of subjects: 300
Study 20932788 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of influences on pain measures (gender, age, height, weight, BMI, depression, anxiety, catastrophizing, SF-36 parameters).
Number of subjects: 300
Study 19202157 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily (n = 118)
Number of subjects: 234
Study 19202157 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 116)
Number of subjects: 234
Study 17005362 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg of etomidate (priming group)
Number of subjects: 46
Study 17005362 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 46
Study 15316868 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 mg/day
Number of subjects: 547
Study 15316868 — intervention group
Group type: COMPARATOR
Intervention: Etidronate 200 mg/day (intermittent treatment)
Number of subjects: 547
Study 11736716 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (6 mg twice daily, increasing to 9 mg twice daily after 6 weeks)
Number of subjects: 70
Study 11736716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 9522321 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (hormonal replacement therapy) as oral or transdermal oestradiol supplemented with progestogen
Number of subjects: 706
Study 9522321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sequential oestrogen plus progestogen
Number of subjects: 706
Study 7526126 — intervention group
Group type: EXPERIMENTAL
Intervention: High-monounsaturated-fat diet (H-MUFA)
Number of subjects: 15
Study 7526126 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (H-CHO)
Number of subjects: 15
Study 3047394 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (1.5 mg/2.5 cm2)
Number of subjects: 18
Study 3047394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29254669 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine (1.5 mg/kg)
Number of subjects: 50
Study 29254669 — intervention group
Group type: COMPARATOR
Intervention: IV morphine (0.1 mg/kg)
Number of subjects: 50
Study 28474075 — intervention group
Group type: EXPERIMENTAL
Intervention: Co‐Cr alloy cast post and core restoration
Number of subjects: 97
Study 28474075 — intervention group
Group type: COMPARATOR
Intervention: everStick fiber post and core restoration
Number of subjects: 97
Study 25060683 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with triamcinolone (BV-TA)
Number of subjects: 111
Study 25060683 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (BV) only
Number of subjects: 111
Study 25060683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 23237793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfer program to mothers
Number of subjects: 0
Study 21698591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular infiltration of 10 ml of 0.25% bupivacaine
Number of subjects: 73
Study 21698591 — intervention group
Group type: COMPARATOR
Intervention: Portal infiltration of 10 ml of 0.25% bupivacaine
Number of subjects: 73
Study 21698591 — intervention group
Group type: COMPARATOR
Intervention: Portal infiltration
Number of subjects: 73
Study 21698591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular infiltration
Number of subjects: 73
Study 18483104 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy
Number of subjects: 76
Study 22343799 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 27
Study 22343799 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 16332474 — intervention group
Group type: COMPARATOR
Intervention: Standard pancreaticoduodenectomy (PD)
Number of subjects: 299
Study 16332474 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical pancreaticoduodenectomy (PD) with distal gastrectomy and retroperitoneal lymphadenectomy
Number of subjects: 299
Study 16332474 — intervention group
Group type: COMPARATOR
Intervention: Standard pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma
Number of subjects: 299
Study 16332474 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma
Number of subjects: 299
Study 16332474 — intervention group
Group type: COMPARATOR
Intervention: Standard resection
Number of subjects: 299
Study 16332474 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical resection
Number of subjects: 299
Study 12785243 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory cues at 115% of mean cadence
Number of subjects: 11
Study 12785243 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory cues at 107.5% of mean cadence
Number of subjects: 11
Study 12785243 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory cues at 85% of mean cadence
Number of subjects: 11
Study 12785243 — intervention group
Group type: COMPARATOR
Intervention: Uncued condition
Number of subjects: 11
Study 9811282 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (Group 1)
Number of subjects: 38
Study 9811282 — intervention group
Group type: COMPARATOR
Intervention: Conversation (Group 2)
Number of subjects: 38
Study 9811282 — intervention group
Group type: COMPARATOR
Intervention: Single breast milk sample collection (Group 3)
Number of subjects: 38
Study 9811282 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported stress
Number of subjects: 38
Study 9811282 — intervention group
Group type: EXPERIMENTAL
Intervention: Success at relaxation (Group 1)
Number of subjects: 38
Study 7662397 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help program (printed materials received through the mail)
Number of subjects: 171
Study 7662397 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 171
Study 2700332 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilizing splint
Number of subjects: 26
Study 2700332 — intervention group
Group type: COMPARATOR
Intervention: Relaxing appliance
Number of subjects: 26
Study 52001 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 341
Study 52001 — intervention group
Group type: COMPARATOR
Intervention: Glucose infusion
Number of subjects: 341
Study 52001 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase and Glucose infusion
Number of subjects: 341
Study 29246820 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose filgrastim (10 µg/kg BW per day)
Number of subjects: 0
Study 29246820 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose filgrastim (5 µg/kg BW per day)
Number of subjects: 0
Study 28587974 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitafloxacin
Number of subjects: 36
Study 28587974 — intervention group
Group type: COMPARATOR
Intervention: Ertapenem
Number of subjects: 36
Study 25117722 — intervention group
Group type: EXPERIMENTAL
Intervention: Training session at 02:00 p.m.
Number of subjects: 9
Study 25117722 — intervention group
Group type: EXPERIMENTAL
Intervention: Training session at 06:00 p.m.
Number of subjects: 9
Study 25117722 — intervention group
Group type: EXPERIMENTAL
Intervention: Training session at 08:00 a.m.
Number of subjects: 9
Study 23172749 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETA) treatment for 1 year
Number of subjects: 40
Study 22039230 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel contact lenses
Number of subjects: 85
Study 22039230 — intervention group
Group type: COMPARATOR
Intervention: Normal, single-vision, spherocylindrical spectacles (Control)
Number of subjects: 85
Study 18304363 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone cessation counselling by a trained nurse
Number of subjects: 318
Study 18304363 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 318
Study 16926353 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (333 U/kg initial dose, followed by 250 U/kg every 12 hours)
Number of subjects: 708
Study 16926353 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (100 IU/kg every 12 hours)
Number of subjects: 708
Study 16926353 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 708
Study 16926353 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin
Number of subjects: 708
Study 12953129 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF mobilized PB and BM
Number of subjects: 63
Study 12953129 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF mobilized BM
Number of subjects: 63
Study 12953129 — intervention group
Group type: COMPARATOR
Intervention: Control grafts (unstimulated BM and PB)
Number of subjects: 63
Study 12953129 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF and GM‐CSF mobilized grafts
Number of subjects: 63
Study 12953129 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF stimulated BM
Number of subjects: 63
Study 12953129 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF stimulated PB
Number of subjects: 63
Study 10899449 — intervention group
Group type: EXPERIMENTAL
Intervention: Catalyzed Signal Amplification system with DYS1 and DYS2 antibodies
Number of subjects: 0
Study 10899449 — intervention group
Group type: COMPARATOR
Intervention: Control patients with DYS1 and DYS2 antibodies
Number of subjects: 0
Study 8834701 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged mental stress by receiving a letter informing of high screening blood pressure (n = 13)
Number of subjects: 26
Study 8834701 — intervention group
Group type: COMPARATOR
Intervention: Neutral letter (n = 13)
Number of subjects: 26
Study 8834701 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during mental arithmetic
Number of subjects: 26
Study 8834701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 26
Study 1563058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position for 15 min after epidural anaesthesia
Number of subjects: 39
Study 1563058 — intervention group
Group type: COMPARATOR
Intervention: Supine position during anaesthesia (control group)
Number of subjects: 39
Study 6609933 — intervention group
Group type: COMPARATOR
Intervention: Oral methylprednisolone 0.5 mg/kg/day for 7 days
Number of subjects: 10
Study 6609933 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone 1.0 mg/kg (single injection)
Number of subjects: 10
Study 30098822 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Manual Therapy (MT) and Diadynamic (DD) currents (MTDD)
Number of subjects: 60
Study 30098822 — intervention group
Group type: COMPARATOR
Intervention: Manual Therapy (MT) alone
Number of subjects: 60
Study 30098822 — intervention group
Group type: COMPARATOR
Intervention: Diadynamic (DD) currents alone
Number of subjects: 60
Study 26787796 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel SGA
Number of subjects: 615
Study 26787796 — intervention group
Group type: EXPERIMENTAL
Intervention: laryngeal mask airway supreme (LMAS)
Number of subjects: 615
Study 26787796 — intervention group
Group type: COMPARATOR
Intervention: current practice
Number of subjects: 615
Study 25620452 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Detection/Executive Function (RD/EF) intervention
Number of subjects: 180
Study 25620452 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Learning/Feminist (SL/F) intervention
Number of subjects: 180
Study 23992154 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Care Units (SCUs)
Number of subjects: 197
Study 23992154 — intervention group
Group type: COMPARATOR
Intervention: Standard beds
Number of subjects: 197
Study 21909466 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable calcium sulfate (ICS) graft
Number of subjects: 56
Study 21909466 — intervention group
Group type: COMPARATOR
Intervention: Demineralized bone matrix (DBM)‐based graft
Number of subjects: 56
Study 18201827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (100,000U intravenously three times a day for 1 week)
Number of subjects: 34
Study 18201827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (40,000U/kg immediately after burn)
Number of subjects: 34
Study 18201827 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine treatment)
Number of subjects: 34
Study 16968874 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (E) 110 mg/m2 followed by paclitaxel (P) 250 mg/m2 followed by intensified CMF (cyclophosphamide 840 mg/m2, methotrexate 47 mg/m2 and fluorouracil 840 mg/m2)
Number of subjects: 595
Study 16968874 — intervention group
Group type: COMPARATOR
Intervention: Four cycles of Epirubicin (E) followed by four cycles of CMF
Number of subjects: 595
Study 15882216 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmucosal anaesthetic patches containing lidocaine (46.1 mg/2 cm(2))
Number of subjects: 40
Study 15882216 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 40
Study 11520478 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapride
Number of subjects: 306
Study 11520478 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 306
Study 11520478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 9391998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone (600 mg/day) plus calcium (500 mg/day)
Number of subjects: 0
Study 9391998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone (400 mg/day) plus conjugated estrogens (0.3 mg/day) plus calcium (500 mg/day)
Number of subjects: 0
Study 9391998 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens (0.3 mg/day) plus calcium (500 mg/day)
Number of subjects: 0
Study 9391998 — intervention group
Group type: COMPARATOR
Intervention: Calcium (500 mg/day)
Number of subjects: 0
Study 7961321 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine inhalation challenge
Number of subjects: 350
Study 7961321 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 350
Study 7961321 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly Dmin variation from age 13
Number of subjects: 350
Study 3308571 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of cefoxitin (2 g)
Number of subjects: 138
Study 3308571 — intervention group
Group type: COMPARATOR
Intervention: Three doses of cefoxitin (2 g, 1 g, and 1 g)
Number of subjects: 138
Study 28950380 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultation
Number of subjects: 112
Study 28950380 — intervention group
Group type: COMPARATOR
Intervention: Fibre-optic bronchoscopy
Number of subjects: 112
Study 28437120 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Oriented Recovery Enhancement (MORE)
Number of subjects: 30
Study 28437120 — intervention group
Group type: COMPARATOR
Intervention: Support Group (SG)
Number of subjects: 30
Study 26427705 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg qid on day 0 and bid on days 1 to 7
Number of subjects: 5
Study 26427705 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 10 mg bid for 7 days
Number of subjects: 5
Study 26427705 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg qid for 7 days
Number of subjects: 5
Study 26427705 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg bid in IMs
Number of subjects: 5
Study 26427705 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg bid in PMs
Number of subjects: 5
Study 24174910 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block using 1 mL·kg(‐1) lidocaine (1%) after 2 mg·kg(‐1) ketamine IV
Number of subjects: 40
Study 24174910 — intervention group
Group type: COMPARATOR
Intervention: 2 mg·kg(‐1) ketamine IV only
Number of subjects: 40
Study 21678045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlower respiratory serious adverse events (NRSAEs) within 30 days post-exacerbation
Number of subjects: 3960
Study 21678045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlower respiratory serious adverse events (NRSAEs) within 180 days post-exacerbation
Number of subjects: 3960
Study 21678045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac events as NRSAEs
Number of subjects: 3960
Study 18344635 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV high-pressure group (n=16)
Number of subjects: 44
Study 18344635 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV low-pressure group (n=14)
Number of subjects: 44
Study 18344635 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=14)
Number of subjects: 44
Study 16555144 — intervention group
Group type: EXPERIMENTAL
Intervention: Family skills training
Number of subjects: 715
Study 16555144 — intervention group
Group type: COMPARATOR
Intervention: Child skills training only
Number of subjects: 715
Study 16555144 — intervention group
Group type: COMPARATOR
Intervention: Parent skills training only
Number of subjects: 715
Study 16555144 — intervention group
Group type: COMPARATOR
Intervention: Parent and child skills training plus family skills training
Number of subjects: 715
Study 16555144 — intervention group
Group type: COMPARATOR
Intervention: Minimal treatment controls
Number of subjects: 715
Study 12679447 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate diet
Number of subjects: 53
Study 12679447 — intervention group
Group type: COMPARATOR
Intervention: Calorie‐restricted low fat diet
Number of subjects: 53
Study 12679447 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 53
Study 10616235 — intervention group
Group type: EXPERIMENTAL
Intervention: Ministernotomy (group M)
Number of subjects: 26
Study 10616235 — intervention group
Group type: COMPARATOR
Intervention: Median sternotomy (group S)
Number of subjects: 26
Study 10616235 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (M and S)
Number of subjects: 26
Study 9457982 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphologic hysteroscopic criteria (presence of endometrial glands presenting a cystic pattern)
Number of subjects: 95
Study 9457982 — intervention group
Group type: COMPARATOR
Intervention: Histology (as a comparison group)
Number of subjects: 95
Study 2033429 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed rGM‐CSF (N = 11)
Number of subjects: 30
Study 2033429 — intervention group
Group type: EXPERIMENTAL
Intervention: rGM‐CSF (N = 6)
Number of subjects: 30
Study 2033429 — intervention group
Group type: COMPARATOR
Intervention: Control (N = 4)
Number of subjects: 30
Study 2033429 — intervention group
Group type: COMPARATOR
Intervention: Control (N = 10)
Number of subjects: 30
Study 2033429 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rGM‐CSF (N = 5)
Number of subjects: 30
Study 7192488 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-miscible vitamin A, 100,000 IU
Number of subjects: 0
Study 7192488 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-miscible vitamin A, 50,000 IU
Number of subjects: 0
Study 7192488 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-miscible vitamin A, greater than 100,000 IU
Number of subjects: 0
Study 30072782 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia (MTH) with slow rewarming for >48 hours
Number of subjects: 97
Study 30072782 — intervention group
Group type: COMPARATOR
Intervention: Mild therapeutic hypothermia (MTH) with slow rewarming for ≤48 hours
Number of subjects: 97
Study 27744007 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3−-rich beetroot juice (140 mL day−1; 8.4 mmol NO3− day−1)
Number of subjects: 17
Study 27744007 — intervention group
Group type: COMPARATOR
Intervention: NO3−-depleted beetroot juice (0.08 mmol NO3− day−1)
Number of subjects: 17
Study 27744007 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3−-rich beetroot juice (NIT)
Number of subjects: 17
Study 27744007 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 17
Study 25702160 — intervention group
Group type: EXPERIMENTAL
Intervention: Alerting tones with prism adaptation (PA) in young adults
Number of subjects: 0
Study 25702160 — intervention group
Group type: EXPERIMENTAL
Intervention: Alerting tones with prism adaptation (PA) in older adults
Number of subjects: 0
Study 23639243 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC+ZDV
Number of subjects: 197
Study 23639243 — intervention group
Group type: COMPARATOR
Intervention: TDF/FTC+EFV
Number of subjects: 197
Study 20884893 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-and-treat (cryotherapy for positive HPV DNA test)
Number of subjects: 6637
Study 20884893 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection-and-treat (cryotherapy for positive visual inspection)
Number of subjects: 6637
Study 20884893 — intervention group
Group type: COMPARATOR
Intervention: Control (delayed evaluation or treatment for 6 months)
Number of subjects: 6637
Study 20884893 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-and-treat
Number of subjects: 6637
Study 20884893 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 6637
Study 20884893 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection-and-treat
Number of subjects: 6637